Literature DB >> 25193375

The emerging molecular architecture of schizophrenia, polygenic risk scores and the clinical implications for gXe research.

James B Kirkbride1.   

Abstract

In this commentary I review the recent paper by Iyegbe et al. on "The emerging molecular architecture of schizophrenia, polygenic risk scores and the clinical implications for gXe research". I discuss how the paper advances our knowledge of polygenic risk scores for use, amongst others, in gene-environment interaction studies and the opportunities and challenges such approaches will bring to our understanding of the epidemiology of psychotic disorders, including schizophrenia.

Entities:  

Mesh:

Year:  2014        PMID: 25193375      PMCID: PMC4165868          DOI: 10.1007/s00127-014-0961-6

Source DB:  PubMed          Journal:  Soc Psychiatry Psychiatr Epidemiol        ISSN: 0933-7954            Impact factor:   4.328


The latest and largest genome-wide association train has just rolled through Nature, bringing with it the exciting news that 128 novel and established genetic loci for schizophrenia have been identified [1]. This news is rightly being heralded as a potentially major breakthrough in our understanding of genes important in the risk of schizophrenia, by both reproducing already established risk genes previously identified in subsamples of the same dataset, as well as identifying 83 previously unknown loci as potential aetiological and therapeutic targets [1]. Putting aside staple epidemiological concerns regarding heterogeneous control sampling of its more than 50 constituent samples, and possible selection biases inherent therein, the increased power to detect genes with small effect sizes brings welcome precision to the field of schizophrenia genetics, as it continues to disentangle the signal from the noise. Such discoveries will also be a boon to researchers investigating the ways in which genetic and environmental influences combine to affect the risk of experiencing schizophrenia and other psychotic and genetically related psychiatric conditions [2]. One possible approach to gene–environment research is outlined by Iyegbe and colleagues [3] in their state-of-science review in a recent issue of Social Psychiatry and Psychiatric Epidemiology, in which they provide the background, rationale, challenges and methodological approaches to using polygenic risk scores in clinical and aetiological practice. Iyegbe et al. [3] begin their article with a generally well-balanced and highly accessible overview of the historical development of the major genetic and environmental discoveries which have been elucidated in schizophrenia research. They are quick to recognise the redundancy in what should now be considered a sterile debate over “genetic” versus “environmental” causes. Given a myriad of genetic and environmental “loci” for schizophrenia dictate low specificity with regard to both exposure and outcome, it is natural to assume that mechanisms beyond main effects must influence the risk of a given psychiatric disorder, or that there are many mechanisms through which psychosis can occur at the individual level. Although discussed here in terms of gene–environment interactions [gXe], other possible mechanisms, including gene expression [4] and gene–environment correlation [5] require careful, equal consideration; both genetic and epidemiological expertise will be vital in developing longitudinal cohort studies capable of investigating such pathways. Such studies sit at the top of a relatively intuitive set of observational designs available in epidemiological research, which have various strengths and limitations depending on the exact research goal or question [6]. The authors [3] are particularly generous in their appraisal of findings in relation to “well-established” and “robust” socio-environmental risk factors associated with schizophrenia risk. Indeed in some cases, epidemiologists themselves may exercise more caution. For some risk factors, such as cannabis use [7] or very severe prenatal malnutrition [8], the evidence base is indeed strong. Elsewhere, however, while there is good epidemiological evidence that environmental factors such as migration [9] and ethnic minority status [10], or urban birth and upbringing [11, 12], are consistently associated with increased incidence, or risk, the exact social, biological or genetic exposures which these markers represent, remain unknown. Further research is required to carefully examine competing hypotheses, which include the influence of social stressors [13] such as discrimination [14, 15], inequality [16] and disadvantage [17], biological stressors [18] such as infection or malnutrition (including vitamin D) or effect modification via as yet untested candidate genes. Just as the large relative risks traditionally associated with a family history of psychosis may (in part) provide a summary measure of the totality of genetic (and shared environmental) risk now more accurately partitioned by genome wide association studies [GWAS], so might the risk associated with urban living or minority position be a summary marker for a range of deleterious environmental or genetic processes operating further along the causal pathway. For example, a recent study of 2.4 million people in Sweden suggests that selection processes (genetic or environmental) operating at the family level may be responsible for associations between deleterious environmental factors and later schizophrenia risk [19]. Indeed, the raison d’etre for any epidemiological study is not only to elucidate large relative risks but to explain variation in risk via careful measurement and scrutiny of other (traditionally, “confounding”) variables. Thus, as psychiatric genetics has traditionally subsumed the environment as a noise term in analyses, even the best epidemiological studies of psychotic disorder may have been limited in their ability to account for residual or unmeasured confounding, from both genetic and environmental factors, wherein the most valuable aetiological clues may lie. The “flaw” spotted by Iyegbe et al. [3] in one of our previous publications on the population impact of such factors and prevention of schizophrenia [20], thus arises from a more general limitation of our discipline; the challenge of conducting epidemiological studies of disorders of very rare incidence, using large representative and unbiased samples, with comprehensive measurement of all the social, biological, neurodevelopmental and genetic factors potentially influencing risk over the life course. As acknowledged in our original report [20] (pp. 7–8), we recognised “that other, unmeasured confounders may be important, including a family history of psychoses…[I]t is unlikely that psychosocial risk factors are often sufficient to cause psychosis, but rather interact with neurodevelopmental or genetic vulnerability.” Thus, we echo and support Iyegbe et al.’s [3] view (pp. 175) that there “is a relative paucity of datasets able to adequately assess the effect of joint exposure to genes and environment, which will be necessary for advancing aetiology and estimating the true proportion of disease which could be prevented by the removal of exposure to either or both sets of factors”. It follows that risk prediction is a major focus of Iyegbe and colleagues’ review [3]. They eloquently outline the basis and method for the development of a polygenic risk score, drawing on available GWAS data. The polygenic score represents the within-person sum of all risk alleles for a given locus of interest multiplied by its (log) odds ratio as identified in a “training” sample of GWAS data. This polygenic score is subject to less sampling error as more data are added from GWAS consortia, but its psychometric properties currently still fall short of predictive validity necessary for use in the general population. More interestingly, however, there is increasing evidence that polygenic scores may be reaching threshold validity for predicting those at high risk of psychosis, which potentially yields exciting opportunities for early intervention research [21]. Iyegbe et al. [3] should be commended for writing a highly comprehensive review in clear, understandable language for epidemiologists and other psychiatric researchers not working regularly with complex GWAS data. In doing so their paper raises a number of questions about the use of polygenic risk scores which could further aid both research, and the non-familiar researcher. One useful next stage, for example, would presumably be to identify the social, clinical, developmental and environmental correlates of high polygenic scores in ultra-high risk samples and test how these then map on to later transition to the development of first episode psychosis. Careful research is needed to determine whether polygenic risk scores can be augmented with information on family history of disorder for the practical identification of at-risk groups, or in order to test putative gXe interactions in schizophrenia. Researchers will need convincing that a polygenic risk score for these purposes can enhance detection of gXe effects over and above those provided by a family history of psychosis, which may be cheaper, easier and more practical to implement in large observational or experimental research designs as a marker for high genetic risk. Iyegbe et al. [3] discuss the potential role of polygenic scores in gXe studies, including under Genome Wide Environment Interaction Studies (GWEIS) approaches. Space and care are devoted to the complexities and controversies involved in detecting gXe interactions (see also [22, 23]), including sample sizes needed to demonstrate their presence, and more problematically in terms of power, their absence. A further challenge to advocates of a polygenic risk approach in gXe studies is to explain how it can enhance the understanding of the molecular architecture of schizophrenia, and the pathways through which polygenic risk might combine with environmental factors to influence the likelihood of schizophrenia. Since there may be several different pathways through which various combinations of genetic and environmental factors act, synergistically or directly, it is unclear how a single polygenic score would help clarify those genes or brain systems involved. One question which arose from Iyegbe et al.’s [3] stimulating review was the extent to which it would be possible to identify “latent” polygenic risk scores which sought to cluster genetic risk according to different theoretical pathways of disease causation (dopaminergic, glutamatergic, GABAergic, calcium channels, etc.). Given theoretical and empirical evidence to suggest that social environmental stressors may act most strongly on genes involved in dopamine sensitization [18, 24], such an approach would presumably increase the a priori theoretical justification and statistical power to detect putative gXe interactions and the mechanisms implicated therein. I commend Iyegbe et al. [3] on a highly readable review of a complex area and hope that this builds on contemporary gXe endeavours [2] to lay the rails for future discourse, collaboration and discovery between the social and genetic sciences.
  23 in total

Review 1.  Migration and schizophrenia: the challenges for European psychiatry and implications for the future.

Authors:  Gerard Hutchinson; Christian Haasen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2004-05       Impact factor: 4.328

Review 2.  The psychosis high-risk state: a comprehensive state-of-the-art review.

Authors:  Paolo Fusar-Poli; Stefan Borgwardt; Andreas Bechdolf; Jean Addington; Anita Riecher-Rössler; Frauke Schultze-Lutter; Matcheri Keshavan; Stephen Wood; Stephan Ruhrmann; Larry J Seidman; Lucia Valmaggia; Tyrone Cannon; Eva Velthorst; Lieuwe De Haan; Barbara Cornblatt; Ilaria Bonoldi; Max Birchwood; Thomas McGlashan; William Carpenter; Patrick McGorry; Joachim Klosterkötter; Philip McGuire; Alison Yung
Journal:  JAMA Psychiatry       Date:  2013-01       Impact factor: 21.596

3.  Effects of family history and place and season of birth on the risk of schizophrenia.

Authors:  P B Mortensen; C B Pedersen; T Westergaard; J Wohlfahrt; H Ewald; O Mors; P K Andersen; M Melbye
Journal:  N Engl J Med       Date:  1999-02-25       Impact factor: 91.245

4.  Prenatal nutrition, epigenetics and schizophrenia risk: can we test causal effects?

Authors:  James B Kirkbride; Ezra Susser; Marija Kundakovic; Jacob K Kresovich; George Davey Smith; Caroline L Relton
Journal:  Epigenomics       Date:  2012-06       Impact factor: 4.778

5.  Schizophrenia and city life.

Authors:  G Lewis; A David; S Andréasson; P Allebeck
Journal:  Lancet       Date:  1992-07-18       Impact factor: 79.321

6.  Psychoses, ethnicity and socio-economic status.

Authors:  J B Kirkbride; D Barker; F Cowden; R Stamps; M Yang; P B Jones; J W Coid
Journal:  Br J Psychiatry       Date:  2008-07       Impact factor: 9.319

7.  Does population density and neighborhood deprivation predict schizophrenia? A nationwide Swedish family-based study of 2.4 million individuals.

Authors:  Amir Sariaslan; Henrik Larsson; Brian D'Onofrio; Niklas Långström; Seena Fazel; Paul Lichtenstein
Journal:  Schizophr Bull       Date:  2014-07-22       Impact factor: 9.306

Review 8.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Authors:  Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

Review 9.  Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations.

Authors:  Jim van Os; Bart P Rutten; Inez Myin-Germeys; Philippe Delespaul; Wolfgang Viechtbauer; Catherine van Zelst; Richard Bruggeman; Ulrich Reininghaus; Craig Morgan; Robin M Murray; Marta Di Forti; Philip McGuire; Lucia R Valmaggia; Matthew J Kempton; Charlotte Gayer-Anderson; Kathryn Hubbard; Stephanie Beards; Simona A Stilo; Adanna Onyejiaka; Francois Bourque; Gemma Modinos; Stefania Tognin; Maria Calem; Michael C O'Donovan; Michael J Owen; Peter Holmans; Nigel Williams; Nicholas Craddock; Alexander Richards; Isla Humphreys; Andreas Meyer-Lindenberg; F Markus Leweke; Heike Tost; Ceren Akdeniz; Cathrin Rohleder; J Malte Bumb; Emanuel Schwarz; Köksal Alptekin; Alp Üçok; Meram Can Saka; E Cem Atbaşoğlu; Sinan Gülöksüz; Guvem Gumus-Akay; Burçin Cihan; Hasan Karadağ; Haldan Soygür; Eylem Şahin Cankurtaran; Semra Ulusoy; Berna Akdede; Tolga Binbay; Ahmet Ayer; Handan Noyan; Gülşah Karadayı; Elçin Akturan; Halis Ulaş; Celso Arango; Mara Parellada; Miguel Bernardo; Julio Sanjuán; Julio Bobes; Manuel Arrojo; Jose Luis Santos; Pedro Cuadrado; José Juan Rodríguez Solano; Angel Carracedo; Enrique García Bernardo; Laura Roldán; Gonzalo López; Bibiana Cabrera; Sabrina Cruz; Eva Ma Díaz Mesa; María Pouso; Estela Jiménez; Teresa Sánchez; Marta Rapado; Emiliano González; Covadonga Martínez; Emilio Sánchez; Ma Soledad Olmeda; Lieuwe de Haan; Eva Velthorst; Mark van der Gaag; Jean-Paul Selten; Daniella van Dam; Elsje van der Ven; Floor van der Meer; Elles Messchaert; Tamar Kraan; Nadine Burger; Marion Leboyer; Andrei Szoke; Franck Schürhoff; Pierre-Michel Llorca; Stéphane Jamain; Andrea Tortelli; Flora Frijda; Jeanne Vilain; Anne-Marie Galliot; Grégoire Baudin; Aziz Ferchiou; Jean-Romain Richard; Ewa Bulzacka; Thomas Charpeaud; Anne-Marie Tronche; Marc De Hert; Ruud van Winkel; Jeroen Decoster; Catherine Derom; Evert Thiery; Nikos C Stefanis; Gabriele Sachs; Harald Aschauer; Iris Lasser; Bernadette Winklbaur; Monika Schlögelhofer; Anita Riecher-Rössler; Stefan Borgwardt; Anna Walter; Fabienne Harrisberger; Renata Smieskova; Charlotte Rapp; Sarah Ittig; Fabienne Soguel-dit-Piquard; Erich Studerus; Joachim Klosterkötter; Stephan Ruhrmann; Julia Paruch; Dominika Julkowski; Desiree Hilboll; Pak C Sham; Stacey S Cherny; Eric Y H Chen; Desmond D Campbell; Miaoxin Li; Carlos María Romeo-Casabona; Aitziber Emaldi Cirión; Asier Urruela Mora; Peter Jones; James Kirkbride; Mary Cannon; Dan Rujescu; Ilaria Tarricone; Domenico Berardi; Elena Bonora; Marco Seri; Thomas Marcacci; Luigi Chiri; Federico Chierzi; Viviana Storbini; Mauro Braca; Maria Gabriella Minenna; Ivonne Donegani; Angelo Fioritti; Daniele La Barbera; Caterina Erika La Cascia; Alice Mulè; Lucia Sideli; Rachele Sartorio; Laura Ferraro; Giada Tripoli; Fabio Seminerio; Anna Maria Marinaro; Patrick McGorry; Barnaby Nelson; G Paul Amminger; Christos Pantelis; Paulo R Menezes; Cristina M Del-Ben; Silvia H Gallo Tenan; Rosana Shuhama; Mirella Ruggeri; Sarah Tosato; Antonio Lasalvia; Chiara Bonetto; Elisa Ira; Merete Nordentoft; Marie-Odile Krebs; Neus Barrantes-Vidal; Paula Cristóbal; Thomas R Kwapil; Elisa Brietzke; Rodrigo A Bressan; Ary Gadelha; Nadja P Maric; Sanja Andric; Marina Mihaljevic; Tijana Mirjanic
Journal:  Schizophr Bull       Date:  2014-05-24       Impact factor: 9.306

10.  Biological insights from 108 schizophrenia-associated genetic loci.

Authors: 
Journal:  Nature       Date:  2014-07-22       Impact factor: 49.962

View more
  3 in total

Review 1.  Neighbourhood level social deprivation and the risk of psychotic disorders: a systematic review.

Authors:  Brian O'Donoghue; Eric Roche; Abbie Lane
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-05-13       Impact factor: 4.328

2.  Novel methods in psychiatric epidemiology.

Authors:  Ulrich Reininghaus; Katherine M Keyes; Craig Morgan
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-07       Impact factor: 4.328

3.  Use of schizophrenia and bipolar disorder polygenic risk scores to identify psychotic disorders.

Authors:  Maria Stella Calafato; Johan H Thygesen; Siri Ranlund; Eirini Zartaloudi; Wiepke Cahn; Benedicto Crespo-Facorro; Álvaro Díez-Revuelta; Marta Di Forti; Mei-Hua Hall; Conrad Iyegbe; Assen Jablensky; Rene Kahn; Luba Kalaydjieva; Eugenia Kravariti; Kuang Lin; Colm McDonald; Andrew M McIntosh; Andrew McQuillin; Marco Picchioni; Dan Rujescu; Madiha Shaikh; Timothea Toulopoulou; Jim Van Os; Evangelos Vassos; Muriel Walshe; John Powell; Cathryn M Lewis; Robin M Murray; Elvira Bramon
Journal:  Br J Psychiatry       Date:  2018-09       Impact factor: 9.319

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.